See more : Viji Finance Limited (VIJIFIN.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Awakn Life Sciences Corp. (AWKNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Awakn Life Sciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Snam S.p.A. (SNMRF) Income Statement Analysis – Financial Results
- NGE Capital Limited (NGE.AX) Income Statement Analysis – Financial Results
- Genting Hong Kong Limited (GTHKF) Income Statement Analysis – Financial Results
- BlackRock MuniYield New Jersey Fund, Inc. (MYJ) Income Statement Analysis – Financial Results
- CleanTech Lithium Plc (CTL.L) Income Statement Analysis – Financial Results
Awakn Life Sciences Corp. (AWKNF)
About Awakn Life Sciences Corp.
Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company is headquartered in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 87.37K | 1.50M | 236.04K | 0.00 |
| Cost of Revenue | 18.30K | 603.53K | 512.87K | 0.00 |
| Gross Profit | 69.08K | 891.81K | -276.83K | 0.00 |
| Gross Profit Ratio | 79.06% | 59.64% | -117.28% | 0.00% |
| Research & Development | 827.82K | 1.57M | 3.31M | 0.00 |
| General & Administrative | 2.73M | 4.06M | 4.40M | 666.73K |
| Selling & Marketing | 439.59K | 1.40M | 1.63M | 103.18K |
| SG&A | 3.17M | 8.51M | 6.54M | 823.07K |
| Other Expenses | 0.00 | -2.37K | 10.35K | 0.00 |
| Operating Expenses | 87.37K | 10.08M | 9.85M | 1.46M |
| Cost & Expenses | 4.00M | 10.69M | 10.03M | 1.46M |
| Interest Income | 87.67K | 305.79K | 0.00 | 13.10K |
| Interest Expense | 0.00 | 266.52K | 205.43K | 0.00 |
| Depreciation & Amortization | 18.30K | 14.41K | 181.41K | 84.00 |
| EBITDA | -3.91M | -5.26M | -16.08M | -840.22K |
| EBITDA Ratio | -4,473.00% | -574.33% | -4,072.48% | 0.00% |
| Operating Income | -3.93M | -9.19M | -9.79M | -840.30K |
| Operating Income Ratio | -4,493.94% | -614.69% | -4,149.34% | 0.00% |
| Total Other Income/Expenses | 255.42K | 306.31K | -6.86M | -652.12K |
| Income Before Tax | -3.67M | -9.65M | -16.47M | -1.48M |
| Income Before Tax Ratio | -4,201.61% | -645.44% | -6,978.45% | 0.00% |
| Income Tax Expense | 0.00 | -509.02K | -525.87K | -215.30K |
| Net Income | -5.10M | -9.14M | -15.95M | -1.26M |
| Net Income Ratio | -5,840.14% | -611.40% | -6,755.65% | 0.00% |
| EPS | -0.09 | -0.36 | -0.73 | -0.10 |
| EPS Diluted | -0.13 | -0.36 | -0.73 | -0.10 |
| Weighted Avg Shares Out | 39.68M | 25.20M | 21.96M | 12.63M |
| Weighted Avg Shares Out (Dil) | 29.07M | 25.20M | 21.96M | 12.63M |
Awakn Life Sciences to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC
Conference hosted by M-Vest, Awakn to present on Thursday, June 22nd at 9:00 A.M. ET Toronto, Ontario--(Newsfile Corp. - June 19, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (the "Company"), a clinical-stage biotechnology company developing...
Awakn Life Sciences currently undervalued say Stifel analysts noting de-risked Phase 3 ketamine trial and clinic momentum
Awakn Life Sciences Corp (NEO:AWKN), a biotechnology company developing psychedelic therapies to treat addiction with a near-term focus on alcohol use disorder (AUD), is at an ideal entry point for investors given the company's de-risked ketamine Phase 3 trial for...
Awakn Life Sciences to Present in Upcoming June 2022 Conferences
Toronto, Ontario--(Newsfile Corp. - June 17, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD)...
Stifel Initiates Coverage On Awakn Life Sciences With A Speculative Buy, $8 Target Price Target
Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock. Awakn is a publicly traded company which trades on the over-the-counter market with the symbol of AWKNF.
Ketamine Therapy Shows Potential In Treatment Of Alcohol Use Disorder, New Study Finds
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:AWKNF) published encouraging data from a Phase II trial looking at ketamine-assisted therapy for the treatment of alcohol use disorder. The company, which is developing clinics and therapies in the UK for the implementation...
Awakn Life Sciences to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th
Toronto, Ontario--(Newsfile Corp. - October 8, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, CEO of...
Awakn Life Sciences Announces Closing of Acquisition of Leading Ketamine-Assisted Psychotherapy Clinic in Norway
Transaction concludes with the launch of "Awakn Clinics Oslo AS" as part of Awakn Life Sciences Nordic ExpansionToronto, Ontario--(Newsfile Corp. - October 5, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a...
Awakn Life SciencesAcquires Exclusive Rights to MDMA Research from Imperial College London
This Was the World's First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for AddictionToronto, Ontario--(Newsfile Corp. - September 23, 2021) - Awakn Life Sciences Corp., (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn) a biotechnology company developing and delivering psychedelic...
Awakn Life Sciences to Present at the Oppenheimer and Maxim Group September Investor Conferences
Toronto, Ontario--(Newsfile Corp. - September 20, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer,...
Awakn Life Sciences to Acquire Leading Ketamine-Assisted Psychotherapy Clinic in Norway
Launches Nordics Regional ExpansionDr. Lowan Stewart, One of Europe's Preeminent Ketamine Physicians, Appointed as Awakn's Regional Director for the NordicsToronto, Ontario--(Newsfile Corp. - September 16, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the...
Source: https://incomestatements.info
Category: Stock Reports